Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration

Joseph J. Tseng, Sushma K. Vance, Kara E. Della Torre, Luis S. Mendonca, Michael J. Cooney, James M. Klancnik, John A. Sorenson, K. Bailey Freund

Research output: Contribution to journalArticlepeer-review

115 Scopus citations

Abstract

Purpose: To describe a series of previously normotensive eyes experiencing sustained elevated intraocular pressure (IOP) associated with long-term intravitreal antivascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD). Patients and Methods: Clinical data were reviewed for 25 eyes of 23 patients with neovascular AMD who had increased IOP while receiving interval doses of intravitreal ranibizumab and/or bevacizumab. All eyes had tolerated multiple anti-VEGF injections in the past without IOP elevations. Results: After a mean of 20.0 anti-VEGF injections (range, 8-40 injections), the mean IOP was 29.8 mm Hg (range, 22-58 mm Hg), compared with a baseline of 16.9 mm Hg (range, 14-21 mm Hg). The mean highest IOP while receiving intravitreal anti-VEGF therapy was 35.8 mm Hg (range, 23-58 mm Hg). Overall, 23 of 25 cases required IOP management. In the remaining 2 cases, anti-VEGF dosing was switched from regular interval dosing to an optical coherence tomography-guided variable regimen, with subsequent improvement in IOP without antiglaucoma treatment. Conclusions: Serial injections of anti-VEGF agents may lead to persistent IOP elevations that require glaucoma therapy. The clinician should recognize this phenomenon, as it can occur even if the patient has tolerated multiple prior injections without IOP elevation. Further exploration of the relationship between anti-VEGF therapy and IOP is needed.

Original languageEnglish
Pages (from-to)241-247
Number of pages7
JournalJournal of Glaucoma
Volume21
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

Keywords

  • anti-VEGF
  • bevacizumab
  • neovascular age-related macular degeneration
  • ocular hyper-tension
  • ranibizumab

Fingerprint

Dive into the research topics of 'Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this